Skip to main content
menu

Wilmot Biobank & Biospecimen Research Center

Wilmot Cancer Institute / Research / Biobank & Biospecimen / Publications

 

Publications

BSR Acknowledgment

The BSR is funded by Wilmot Cancer Institute. Any scholarly works (manuscripts, posters, presentations) that leverage BSR materials and/or services for data generation should acknowledge both Wilmot Cancer Institute and the BSR. Proper recognition allows us to measure the impact of our work and supports our initiatives in obtaining sponsored funding. In addition, any BSR personnel who make a substantial intellectual or experimental contribution are deserving of further recognition as co-author on scholarly works at the discretion of the Director and Principal Investigator. Please send citations of any published material to the BSR Director.

Example: [Sample/Service] was provided by the Wilmot Biobank Shared Resource at the University of Rochester Medical Center, which receives financial support from sponsor name (grant number). We especially thank [staff name], for their assistance with [technique/technology].

BSR Description for Grant Proposals

The Biobank Shared Resource (BSR) supports human tissue research at the Wilmot Cancer Institute by offering access to an extensive catalog of clinically annotated biospecimens and comprehensive clinical study consultation and support. Within the BSR, the Wilmot Biobank (WBB) currently inventories over 10,000 specimens procured from approximately 1,000 cases. Sample derivatives include formalin-fixed paraffin-embedded (FFPE) and cryopreserved tumor, adjacent normal, and lymph node tissues, as well as paired blood derivatives (plasma, serum, buffycoat). Aside from prospective tissue banking, the WBB also supports study-specific subject enrollment and tissue collection based on project needs. Detailed standard operating procedures are followed for every procurement, including the implementation of Standard PREanalytical Code (SPREC) annotation for preanalytical quality control. Specimen inventory and corresponding de-identified subject/case information are securely accessible to users through the Bio-Lab Informatics System (BLIS) web-based interface. The WBB BLIS interface reports the subject/disease/sample-level data elements recommended by Biospecimen Reporting for Improved Study Quality (BRISQ) guidelines, and more comprehensive data manifests are made available to users on a case-by-case basis upon request.

Highlights

2023

2022

2021

2019